<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614352</url>
  </required_header>
  <id_info>
    <org_study_id>AGCA_BE_1501</org_study_id>
    <nct_id>NCT02614352</nct_id>
  </id_info>
  <brief_title>Investigate a Pharmacokinetic Characteristics and the Safety of AG1502 in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <brief_summary>
    <textblock>
      Primary object : Evaluate pharmacokinetic property AG1502 and Candesartan 32mg and
      Atorvastatin 40mg in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (candesartan cilexetil)</measure>
    <time_frame>0,0.5,1,2,3,4,5,6,8,10,12,24,48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast (candesartan cilexetil)</measure>
    <time_frame>0,0.5,1,2,3,4,5,6,8,10,12,24,48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Atorvastatin)</measure>
    <time_frame>0,0.25,0.5,0.75,1,1.333,1.667,2,3,4,6,8,12,24,48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast (Atorvastatin)</measure>
    <time_frame>0,0.25,0.5,0.75,1,1.333,1.667,2,3,4,6,8,12,24,48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>AG1502</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan + Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin + Candesartan</intervention_name>
    <arm_group_label>AG1502</arm_group_label>
    <arm_group_label>Candesartan + Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG1502</intervention_name>
    <arm_group_label>AG1502</arm_group_label>
    <arm_group_label>Candesartan + Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy males 19 to 45 years at screening.

          -  BMI 18-29 kg/m2

        Exclusion Criteria:

          -  History of cardiovascular, respiratory, hepatic, renal, neuropsychiatric, endocrine,
             hematologic disease

          -  Hypersensitivity reactions to drugs or significant hypersensitivity reactions in the
             history of Candesartan and Atorvastatin

          -  Hypotension (DBP ≤ 100 mmHg or SBP ≤ 95mmHg) and hypertension (SBP ≥ 150 mmHg or DBP ≥
             95 mmHg)

          -  Gastrointestinal disease affected the absorption of medications

          -  Genetic disease of Galactose intolerance, Lapp lactose deficiency or glucose-galactose
             malabsorption

          -  AST or ALT &gt; 2 x normal range

          -  Total bilirubin &gt; 2.0 mg/dl

          -  CK &gt; 2 x normal range

          -  eGFR &lt; 60 mL/min/1.73m2

          -  Subject who have drunken habitually (alcohol more than 21 units/week, 1 unit = 10 g =
             12.5 mL of pure alcohol) or who are unable to quit drinking during this study

          -  Subject who have smoke habitually more than 10 cigarettes/day or who are unable to
             quit smoking during this study

          -  Subject who treated with any investigational drugs within 90 days before the
             administration of investigational drug

          -  Previously donate whole blood within 60 days or component blood within 30 days or
             transfusion within 30 days

          -  Subject who treated with any drug within 30 days can affect absorption, distribution,
             metabolism, excretion of candesartan or atorvastatin

          -  Subject who treated with any Rx only drug or herbal drug within 14 days and any OTC
             within 7 days

          -  History of drug abuse

          -  Genetic neuromuscular disorder or family history of neuromuscular disorder

          -  Unusual diet affected the absorption, distribution, metabolism, excretion of
             medications

          -  Subjects deemed ineligible by investigator based on other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>JINHYUNG KIM</last_name>
    <email>agpp@ahn-gook.com</email>
  </overall_contact>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

